site stats

Jcog0407

WebJCOG0407：初回化学療法不応(フッ化ピリミジン系抗がん剤を含む化学療法に対して不応)の 腹膜転移を有する進行・再発胃癌に対する best available 5-FU 療法 vs paclitaxel少 … Web5 feb 2009 · The randomized phase II study JCOG0407 compares the best available 5-FU with weekly paclitaxel after failure in first-line chemotherapy containing 5-FU. From the …

Randomized phase II study of second-line chemotherapy …

Web16 feb 2015 · Our data suggest unique trends of PM and the present treatment strategy for PM appears to be reasonable. However, there is currently no widely accepted specific treatment for PM; JCOG failed to demonstrate a clear strategy in two trials limited only to patients with PM (JCOG0106 and JCOG0407). Web17 giu 2024 · Nishina T, Boku N, Gotoh M, Shimada Y, Hamamoto Y, Yasui H, Yamaguchi K, Kawai H, Nakayama N, Amagai K, et al: Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to … johnston medical hospital clayton nc https://glammedupbydior.com

Toward a Treatment Sequencing Strategy: A Systematic Review of ...

WebNorisuke NAKAYAMA Cited by 900 of Kanagawa Cancer Center, Yokohama Read 77 publications Contact Norisuke NAKAYAMA WebRCTs that compared monotherapies included the JCOG0407 trial, where paclitaxel improved mPFS by 1.3 months compared with 5-FU . This PFS benefit appeared to outweigh the toxicity profile. The DREAM study assessed the efficacy of DHP107, an oral paclitaxel, in patients with advanced gastric cancer after failure of first-line therapy . Web30 set 2016 · Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407). johnston memorial hospital abingdon va phone

Altmetric – Randomized phase II study of second-line …

Category:Randomized phase II study of best-available 5-fluorouracil (5-FU ...

Tags:Jcog0407

Jcog0407

2007 Corolla P0441 and P0455 codes Toyota Nation Forum

http://www.jcog.jp/document/s_0407.pdf Weblimited only to patients with PM (JCOG0106 and JCOG0407). Japanese investigators are attempting to establish a PM limited strategy in one of two manners: one group of investi-gators intends to achieve a survival benefit by intraperitoneal direct infusional chemotherapy (21), similar to the treatment

Jcog0407

Did you know?

WebRandomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric … Weblimited only to patients with PM (JCOG0106 and JCOG0407). Japanese investigators are attempting to establish a PM limited strategy in one of two manners: one group of investi …

WebFingerprint Dive into the research topics of 'Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407)'. WebNishina T, Boku N, Gotoh M, Shimada Y, Hamamoto Y, Yasui H, Yamaguchi K, Kawai H, Nakayama N, Amagai K, Mizusawa J, Nakamura K, Shirao K, Ohtsu A. Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal …

Web25 feb 2011 · Progression-free survival (PFS) and time to progression (TTP) have been reported to correlate with overall survival (OS) in several types of cancers. To our knowledge, however, their use in the evaluation of new agents for AGC has not been investigated. We evaluated the potential of PFS and TTP to act as surrogates of OS in … Web16 nov 2024 · Introduction. Gastric cancer is a common malignant disease with high incidence and mortality rates worldwide ().Scirrhous gastric cancer accounts for 10 20% of all gastric cancers and is characterized by an abundant stroma in comparison with medullary carcinomas, which are characterized by scant stroma ().Despite recent advances in the …

Web17 giu 2024 · The aim of the present study was to investigate the effect of the long noncoding RNA HIT000218960 on gastric cancer cell resistance to 5‑fluorouracil (5‑FU) and to explore the underlying molecular mechanism. HIT000218960 expression was measured in gastric cancer tissues and cells lines using reverse transcription‑quantitative PCR and …

Web1 nov 2002 · The mode of action of 5-fluorouracil (5-FU) was evaluated in patients with advanced colon cancer treated preoperatively with 5-FU.After obtaining informed consent, 30 patients were randomized into three groups: untreated controls (n = 16), continuous intravenous infusion of 5-FU for 5 days at a dose of 320 mg/m2 (CIV group, n = 6), or … johnston medical center ncWebRandomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric … johnston meier insurance langley bcWeb9 feb 2011 · Takiuchi H, Fukuda H, Boku N, Shimada Y, Nasu J, Hamamoto Y, date assessing survival and (iv) date of death. et al. Randomized phase II study of best-available 5-fluorouracil (5-FU) versus weekly paclitaxel in gastric cancer (GC) with peritoneal metastasis (PM) refractory to 5-FU-containing regimens (JCOG0407). johnston memorial hospital abingdon